WO1994017106A1 - Storage and delivery of purified protein reagents with carrier wax - Google Patents
Storage and delivery of purified protein reagents with carrier wax Download PDFInfo
- Publication number
- WO1994017106A1 WO1994017106A1 PCT/US1994/000560 US9400560W WO9417106A1 WO 1994017106 A1 WO1994017106 A1 WO 1994017106A1 US 9400560 W US9400560 W US 9400560W WO 9417106 A1 WO9417106 A1 WO 9417106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reagent
- wax
- preparation
- carrier
- mixture
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
Abstract
A method and preparation for the storage and delivery of purified protein reagents is disclosed. In one aspect, the preparation comprises an amount of a first wax carrier, the first wax carrier having a first melting point, and an amount of a first reagent, wherein first reagent is a substantially purified preparation of a protein reagent. The first wax carrier and the first reagent are combined to form a solid mixture when stored at a temperature less than the first melting point.
Description
STORAGE AND DELIVERY OF PURIFIED PROTEIN REAGENTS WITH CARRIER WAX
Background Of The Invention
Technical Field
In general, the field of the present invention is the stabilization and delivery of purified protein reagents for chemical and biochemical reactions . Specifically, the field of the present invention is the stabilization of reagents such as buffered enzymes and other proteins by combining the reagents with a carrier wax.
Background Art
In a biochemical or chemical reaction it is frequently necessary to combine proteins with other reagents. Typically, proteins are delivered from aqueous solutions or suspensions or from freeze-dried material .
There are many problems associated with using aqueous solutions for delivery. Proteins in an aqueous solution or suspension may be subject to rapid decomposition and loss of activity. Therefore, aqueous solutions or suspensions must usually be stored at a low temperature. Additionally, it is difficult to combine an aqueous reagent solution with a general reaction mixture without the reagents reacting immediately. Pipetting and
dispensing aqueous reagents can be subject to measurement errors. It is also difficult to automate the delivery of aqueous reagents. There is always a potential for cross- contamination when aqueous reagents are repetitively pipetted from mixture to mixture.
Another method for storage and delivery of protein reagents involves drying the reagent. However, freeze- drying and other drying methods must rely on special drying and storage processes to stabilize and deliver reagents for molecular manipulations. For example, WO 87/00196 describes a method for the preservation of biological samples by drying in the presence of trehalose. US patent 5,098,893 describes storage of material in a glassy or rubbery composition consisting of water-soluble or water-swellable carbohydrates and derivatives. EPA 0298669 describes an apparatus and method for performing nucleic acid manipulations utilizing predetermined amounts of reagents in a dry state. WO 84/03715 and WO 84/03444 describe a method in which reagents and antibodies may be provided in lyophilized form. Expensive and cumbersome methods and equipment, such as vacuum ovens, are required to preserve and deliver dried reagents .
What is needed in the art of molecular biology is an improved method of storing and delivering protein reagents in a biochemical or chemical reaction mixture. The present invention relates to a method of storing and
delivering protein reagents by combining the reagents with a wax carrier material .
Clinical tissue samples have been stored in paraffin to preserve biologically inactive material for clinical sectioning and subsequent microscopic visualization. DNA has been extracted for PCR amplification from tissue samples prepared for routine histopathological examinations (Goelz et. aJL.. , Bioche . Biophys . Res. Co mun. 130: 118-126, 1985). RNA has been extracted and PCR-amplified from paraffin-embedded human tissue samples (Stanta and Schneider, BioTechnigues . 11: 304-308, 1991.)
Wax has been used as an addition to enzymatic reactions. For example, a recent refinement in the polymerase chain reaction (PCR) process has been the use of AmpliWax™ (Perkin Elmer Cetus) and the development of the "Hot Start technique" . These refinements involve the replacement of mineral oil with a wax pellet as a vapor barrier and to increase amplification specificity (Chou et al. , Nucl. Acids Res. 20 [7] 1717-1723, 1992). WO 91/12342 discloses the use of waxes and greases as vapor barriers in PCR reactions. Additionally, WO 91/12342 discloses subsets of PCR reagents, such as Mg+2, as aqueous emulsions in a grease or wax barrier.
Disclosure Of Invention
The present invention is a reagent preparation comprising a wax carrier and a substantially purified preparation of a protein reagent, wherein the wax carrier and the reagent form a solid mixture.
Preferably, the carrier wax has a melting temperature above approximately room temperature and the reagent is an enzyme. Preferably, enzyme storage or reaction buffers are combined in the preparation.
The present invention is also a method of delivering a protein reagent in a chemical reaction. First, a portion of a first reagent is added to a portion of a liquified carrier wax. The first reagent is a substantially purified preparation of a protein. A mixture is formed by this addition. The mixture is cooled for a sufficient amount of time at a sufficiently low temperature so that the mixture solidifies . The solid mixture is exposed to a second reagent, thus forming a reaction combination. The first reagent is released, and the first and second reagent are free to react with one another.
Preferably, the releasing of the first reagent is by either raising the temperature of the reaction mixture to a temperature greater than or equal to the melting point of the carrier wax or by the addition of a solvent capable of dissolving the carrier wax.
The present invention is also a method of preparing a stabilized protein reagent. This method comprises the steps of combining a substantially purified preparation of reagent with a carrier wax. Both the carrier wax and the reagent preparation are preferably in a liquid form. The combined reagent and carrier wax mixture is cooled at a sufficiently low temperature and for a sufficient time so that the combined mixture solidifies.
One object of the present invention is to provide a protein reagent preparation capable of room temperature storage.
Another object of the present invention is to deliver protein reagents in a chemical reaction in such a manner that the reagent is initially in an inactive form and is subsequently released to an active form.
Another object of the present invention is to provide a rapid method for creating a stabilized protein reagent.
It is a feature of the present invention that the storage and delivery method is easily and inexpensively accomplished.
It is an advantage of the present invention that reagents may be stored at room temperature.
It is another advantage of the present invention that many different waxes may be used as carriers.
Other aspects, objects and advantages of this invention will become apparent from a study of the specification and claims.
Best Modes For Carrying Out The Invention
1. In General
The present invention is a preparation and method for storing and delivering protein reagents in a manner that permits room temperature storage with a minimal amount of loss of reagent activity. By "protein reagent" we mean any protein or peptide substance that could be used in a chemical or biochemical reaction, such as enzymes, peptide hormones, structural proteins, amino acids, antibodies, molecules containing protein groups (such as glycoproteins) , and proteins conjugated to nucleic acids. By "substantially pure preparation of a reagent" we mean that the reagent preparation does not contain substantial amounts of a substance that would be detrimental to the ultimate reagent activity.
To create a stabilized reagent, typically a liquified form of the reagent is first added to a liquified form of a carrier material. Alternatively, the purified protein reagent may be in solid form, such as when freeze-dried or dried by evaporative methods . Either the liquified or dried form of the protein reagent
may preferably be obtained from a purified enzyme preparation. In the examples below, we obtained liquified protein reagent from commercial enzyme preparations. The carrier material is a wax and is described below. A liquified form of the carrier material may be prepared by heating the carrier material to its melting point. The liquified reagent and the liquified carrier material are mixed and immediately cooled to form a solid. We call this procedure "co-solidification".
The present invention is suitable for more than one protein reagent to be co-solidified. It could be advantageous in a biochemical or chemical reaction to add one aliquot containing several different protein reagents to a reaction.
Once the reagent has been co-solidified with the carrier material, the reagent is stable at room temperature storage for extended periods of time. For example, the Examples below disclose that the enzyme Bst E II can be stored at 37° C for at least six weeks after co-solidification. C.M13HRP conjugate can be stored for at least one week at 37° C and Tth restriction enzyme can be stored at least six weeks at room temperature. Additionally, we show that protein reagents in combination with other PCR reagents are stable at least for six weeks at room temperature.
The present invention is also a method of delivering reagents in a chemical or biochemical reaction. The delivery of a reagent in accordance with the present invention is by combining a co-solidified protein reagent and an aqueous solution that preferably contains other reagents meant to react to the co-solidified reagents . The co-solidified reagent is released from the carrier wax. Preferably, this release is affected by subjecting the entire mixture to a temperature that exceeds the melting point of the carrier wax or by adding a solvent, such as xylene, which dissolves the carrier wax.
Alternatively, two separately co-solidified groups of reagents, such as an enzyme and a buffer or two different enzymes, may be combined in a reaction. When the reagents are released from the carrier wax, for example by subjecting both co-solidified reagents to a temperature higher than the melting temperature of both carrier waxes, the reagents are combined and the chemical reaction can begin. Alternatively, a first co-solidified reagent in a carrier wax with a first melting point may be coated with a second co-solidified reagent in a carrier wax with a second melting temperature, preferably a lower melting temperature. In this manner, one may selectively release the second reagent to a chemical reaction by heating the reaction to the melting point of the second carrier wax
and then, upon raising the temperature of the mixture to the first melting point, release the first reagent.
After release of the reagent from the carrier wax, the carrier wax will form a separate layer on the reaction surface. This layer may be removed, preferably by xylene or with a pipette. Alternatively, this layer may remain in place to form a vapor barrier for the reaction mixture and prohibit evaporation of the reaction mixture. One may remove the carrier wax with xylene or toluene, preferably by adding the solvent to the co- solidified mixture, incubating at 37 °C and vortexing the mixture. The solvent will dissolve the wax, which can then be extracted or evaporated. A concentrated stock of the protein reagent is preferably mixed with the carrier wax. In this manner, a small amount of the co-solidified product would need to be added to the reaction mixture to deliver a sufficient quantity of the reagent. Additionally, a concentrated protein reagent provides more stability for the protein. A concentrated solution of reagents might contain enzymes, buffer, salts and nucleotides . This solution is prepared using suitable methods known in the art of molecular biology. Generally, the co-solidified mixture is formulated such that the appropriate reaction concentrations of individual active materials will be delivered.
The co-solidified reagents are stored below the melting point of carrier material. Preferably, the materials are stored at room temperature.
2. Protein Reagents
Protein reagents that are suitable for the present invention include enzymes, peptides, structural proteins, amino acids, antibodies, protein conjugates with nucleic acids, and antibody conjugates. However, other protein reagents are suitable.
Protein reagents suitable for the present invention will lose minimal activity when added to a carrier wax at the melting temperature of the carrier wax. Enzymes are particularly advantageous choices as reagents . Some enzymes, such as the restriction enzyme Hind III, are capable of brief incubation at 60 - 70° C, the melting point of a preferable wax carrier, although these reagents would be unstable at a prolonged exposure to this temperature. Preferable enzymes that may be stabilized and delivered by the present invention are restriction enzymes, DNA ligase, RNA polymerase, and reverse transcriptase.
The present invention is particularly useful for the delivery of thermostable enzymes . Preferred thermostable enzymes are DNA polymerase from thermophilic bacteria and restriction enzymes such as Bst E II, Tag I and Tth III.
Reaction buffers can be added to the stabilized mixture and delivered by the present invention.
One method of determining whether a protein would be a suitable reagent for the present invention is to combine the protein with a carrier wax and determine the activity of the protein after a test storage period. A suitable test storage period would be room temperature storage for two weeks. If the preparation still exhibited requisite protein characteristics, such as enzyme activity if the protein is an enzyme or structural integrity if the preparation is a structural protein, then the protein is a suitable reagent. It is not necessary that the reconstituted protein preparation exhibit 100% of the examined characteristic. For instance, an enzyme may lose some activity in storage and still be a useful preparation. In general, an enzyme should not lose more than 50% enzyme activity in a two week room temperature storage and a structural protein should not degrade more than 50% in a two week room temperature storage. Note that in many types of protein stabilization methods, a large percentage of the ultimate loss takes place during the initial procedure.
3. Carrier Waxes .
By "carrier wax" we mean any of a group of substances composed of hydrocarbons, alcohols, fatty
acids and esters that are solid at ambient temperature. These substances may be of plant or animal origin and contain principally esters of higher fatty acids and higher alcohols, free fatty acids and alcohols, and saturated hydrocarbons. A suitable carrier wax will be heat-sensitive such that the carrier will be liquid at a certain temperature and solid at a lower temperature. Additionally, a suitable wax will not be soluble or swellable in an aqueous solution. Preferably, the carrier wax is selected from material that has a melting point above room temperature. Most preferably, the carrier wax is selected from material that has a melting point above 37° C so that at normal variations of room temperature the co-solidified material is always a solid. Selection of a suitable carrier material is dependent upon the temperature stability of the reagent. The reagent must remain stable at the melting temperature of the carrier wax because both materials must be maintained, at least for a brief period of time (preferably 2 - 3 minutes), at the melting temperature of the carrier wax. Examples of waxes particularly suitable for the present invention are paraffin, AmpliWax PCR Gem 100 (tradename of Perkin Elmer Cetus) and Polyfin (trade name of Poly-sciences). However, many other waxes are equally suitable.
One method of determining whether a candidate carrier wax is suitable for the present invention is to
co-solidify the candidate wax with an enzyme or other protein known to be successfully stored in wax. The examples below disclose several restriction enzymes, DNA polymerases, and DNA ligase which would all be suitable test proteins. After co-solidification at a test period of time, for example, room temperature storage for two weeks, the co-solidified mixture is melted and the activity of the protein measured. If a requisite amount of protein activity is obtained after this test-storage period, then the candidate wax is suitable for the present invention. Control samples of the same enzyme or protein stored without wax can be stored alongside the co-solidified mixture to determine the activity differential due to storage in a carrier wax. If the ultimate goal is stabilization, a successful carrier wax will enable at least a two-fold difference in activity after a two-week room temperature storage period.
We envision that one could prepare suitable waxes by combinations of waxes . This may be to obtain a wax with a suitable melting point or to obtain a wax with other useful characteristics.
EXAMPLES
In the examples below, we have specifically demonstrated that the present invention is suitable for enzymes useful in PCR reactions, thermophilic restriction
enzymes, DNA sequencing enzymes, conjugated antibodies, and DNA ligase. These examples are meant to be specific embodiments of the present invention and are not meant to imply that other protein reagents are not equally suitable for the present invention. Additionally, we have demonstrated that lysozyme is a suitable protein reagent.
Example 1; Polymerase Chain Reaction ..PCR
In general, PCR enables one to amplify specific segments of nucleic acid by annealing specific primers to the nucleic acid that one wishes to amplify and allowing a polymerase enzyme to polymerize the nucleic acid between the two primers. The reaction product is heated to dislodge the primers from their specific targets. When the synthesized nucleic acid anneals with other primers in the reaction mixture, an exponentially increasing amount of nucleic acid is formed. We demonstrated that different combinations of protein reagents and other reagents involved in PCR could be stored and delivered by the present invention. In Example 1(A) the polymerase is co-solidified with buffers and nucleotides. In Example 1(B), the primers, the nucleotides, the enzyme and the PCR buffers are stored. Of course, many different combinations of protein with other components are possible.
In the following reactions, when AmpliWax was used for co-solidification, a standard method was used to add the liquified reagent to the carrier wax. One pellet of the AmpliWax was melted at 65° C for two to three minutes. The liquified reagent was added to the side of the tube and the mixture remelted at 65° C. The mixture was then vortexed gently. The reaction was cooled at 22° C for two minutes. After cooling, the reaction was in a solid form. To mix the reactants in Example 1(A), water, primers and DNA were placed on top of the co-solidified reagents. The mixture was melted, vortexed and cooled. After cooling, the wax layer formed a solid shell at the top of the reaction mixture. The wax layer was not disturbed and the PCR reaction was subjected to the standard reaction conditions. In Example 1(B), the wax was melted, vortexed and cooled. The reagents were moved as a layer from beneath the wax.
As a test of storage stability, the co-solidified reagents were stored at various temperatures for various periods of time. The reagents in Examples 1(A) and 1(B) were stored for up to six weeks at ambient temperature.
A. Storage of DNA Polymerase
Taq DNA Polymerase (0.5μl, 2.5 units; Perkin Elmer or Pharmacia) was added to one liquified AmpliWax PCR Gem
(Perkin Elmer) with 2 μl of 50x PCR Buffer (0.5 M Tris- HC1, pH 8.3, 2.5 M KC1, 0.075 M MgCl2) and lul of lOOx Polymerization Mix (20 mM each of dGTP, dATP, dTTP, dCTP; Pharmacia). The co-solidified material was stored for up to six weeks. One sample was stored at 37° for four weeks .
PCR amplification was performed by adding 100 ul of water containing 1 ng of pBR322 DNA linearized with PvuII and complementary primers specific for the pBR322 sequence (50 pmoles each of SF4 and SF5 primers,
Pharmacia) to the co-solidified mixture. The reaction mix was placed in a Perkin-Elmer Cetus thermocycler (Perkin- Elmer Cetus, Norwalk, CT) under the following temperature cycling protocol: 30 cycles, each cycle consisting of denaturation at 94°C for 1 minute, annealing at 55°C for 2 minutes, and extension at 72°C for 2 minutes. As a control, an identical PCR reaction was performed with reagents that had not been co-solidified or stored at elevated temperatures . To verify the efficacy of the PCR reaction, 10 ul of the completed PCR reaction was analyzed by agarose gel electrophoresis in lx TBE buffer containing ethidium bromide. An amplification product of approximately 350 bp of approximately the same yield was observed with both fresh reagents (control) and wax-embedded reagents stored
at 37°C for four weeks. Results were similar with all the stored samples.
B. Heat-Soaked PCR
50 pmoles each of SF4 and SF5, 0.2 ml. each of dNTPs (Pharmacia), 2.5 units AmpliTaq and PCR Buffer (Perkin Elmer) were co-solidified and stored. The co-solidi ied mixture was melted, as described above, and the reagents removed from beneath the wax layer. 90 ul of water containing 1 ng of pBR322 DNA cut with PvuII was heat denatured at 94°C for 30 min. and added to the reagents.
PCR reaction was performed as above. The results with co-solidified reagents were comparable to control reactions with standard Heat-Soaked reagents and technique (Ruanoet et. aL.. , BioTechnigues 13 (2): 266-274 (1992)). We obtained nucleic acid of equivalent amounts and size. Therefore, the protein reagent was successfully stored and delivered by the manner of the present invention.
Example 2: Thermophilic Restriction Enzymes
Thermophilic restriction enzymes (one unit) were co- solidified with AmpliWax as described in Example 1.
A. DNA Restriction Analyses: Bst EII
One unit of Bst EII was co-solidified with carrier wax and stored at 37 °C for six weeks. Hydrolysis of lambda DNA (0.5 μg) was performed at 60 °C for 1 hr with both fresh (control) and the co-solidified enzyme. Lambda DNA in buffer was added on top of the co- solidified mixture. The entire mix was melted at 65 °C, vortexed, and incubated at 60 °C for digestion. Complete hydrolysis of lambda DNA was observed with wax-embedded Bst EII. However, Bst EII stored at 37°C without carrier wax was completely inactive after ten days .
B. DNA Restriction Analyses: Tag I
One unit of Tag I was co-solidified with carrier wax as above for six weeks at room temperature. Hydrolysis of lambda DNA (0.5μg) was performed at 65 °C for 1 hr with both fresh and co-solidified enzymes. Complete hydrolysis of lambda DNA was observed with the co- solidified Tag I .
C. DNA Restriction Analyses: Tth 111 I
One unit of Tth 111 I was co-solidified with carrier wax as above. Hydrolysis of lambda DNA (0.5 μg) was
performed at 65 °C for 1 hr with fresh and wax-embedded enzyme that had been stored at room temperature for six weeks. Complete hydrolysis of lambda DNA was observed with co-solidified Tth 111 I.
Example 3: DNA Seguencing With Tth/Bst DNA Polymerases
Control sequencing reactions were performed according to procedures recommended by the manufacturers (GeneAtaq Kit; Pharmacia and BioRad for the Bst reaction) .
Two units of Bst or one unit of Tth were co- solidified with wax as in Example 1 and stored for one week at room temperature for Bst or two weeks at room temperature for Tth. The sequencing reaction was as follows:
Annealed template and primers and P- -dATP were added to the co-solidified sample. The mix was heated until melting, vortexed and cooled. The solution was removed from beneath the wax for the subsequent reaction. Sequencing results with co-solidified enzymes were comparable to control reactions . We observed equivalent extension and lack of background.
Example 4: HRP-Conjugated 0.-M13 antibody:
-M13 HRP conjugate, a sheep antibody to M13 conjugated to horseradish peroxidase (HRP), was co- solidified with carrier wax as described in Example 1. The co-solidified product was stored for one week at 22 °C or 37 °C. HRP was conjugated to c_M13 antibodies using the periodate coupling method (Antibodies, A Laboratory Manual; Ed:Harlow and Lane, 1988). To demonstrate binding, microtiter plate wells were coated with M13K07 phage supernatant. The αM13HRP conjugate was bound by standard methods. The wells were washed and a colormetric substrate was added. The color change, indicative of the amount of functional conjugates bound to the M13K07 coated on the well, was measured.
After one week at 22 °C or 37 °C, co-solidified - M13 HRP conjugate showed good signal on ELISA while α-M13 HRP conjugate that had not been co-solidified showed background levels, thus demonstrating that the wax can stabilize the -M13 HRP conjugate. Co-solidified antibody that had been stored for one week at 22 °C or 37 °C showed approximately half of the signal obtained with a control conjugate that had been stored at 4 °C without co-solidification.
Example 5 : DNA Ligation
Ampligase, a thermostable T4 DNA ligase (1 Unit, Epicenter, Madison) was co-solidified with melted AmpliWax and stored for one day at 37 °C. Ligation of Sma I-/Sal I-cut lambda DNA with fresh and wax-embedded ligase showed successful results. DNA, buffer and water were added to the top of the co-solidified preparation. The entire mixture was melted by incubating at 65 °C for 10 minutes, vortexed and cooled. The ligation reaction was at 70 °C for 10 minutes. Ligation products were compared to controls by pattern of bands after electrophoresis .
Example 6: Hind III
One unit of Hind III (Pharmacia) was co-solidified with AmpliWax, as described above. A mixture of 1 μg lambda DNA, reaction buffer and water was added to the co-solidified enzyme. The tube was heated at 65 °C until melted (about two minutes), vortexed and cooled to room temperature. Digestion was performed at 37 °C for one hour. Results indicated that the lambda DNA had been digested. The Lambda DNA appeared to be completely digested, as did the DNA sample incubated with the non- co-solidified Hind III.
Example 7 : Klenow Fragment
5-10 units of Klenow DNA polymerase (Pharmacia) were co-solidified, as above, with AmpliWax. The preparation was not stored and was used immediately. Annealed template and primer was added to the co-solidified mixture. The mixture was heated at 65 °C for about two minutes, vortexed, and cooled to room temperature. The liquified reagents were removed from beneath the wax layer and transferred to a new tube. DNA sequencing reactions were performed with BaseMaster Sequencing Kit according to instructions. Results were comparable to those using fresh enzyme. We observed equivalent extensions and low backgrounds.
Example 8: Paraffin Wax
Reagents for PCR amplification (buffer, nucleotides and Taq DNA Polymerase) were co-solidified as above in Paraffin Wax and successfully stored and delivered. 10 ul of 10X PCR Buffer, lul of 20mM dNTPs and lul of Taq DNA Polymerase (Pharmacia) were co-solidified in approximately 20 mg Paraffin Wax from Aldrich Chemical Company, Inc. (Product number 32,720-4). The Paraffin Wax melted at about 65 °C. Water, primers (50pmoles each) and DNA template (lng) were added to the co- solidified reagents. The tube was heated to 65 °C,
vortexed and cooled to room temperature. PCR amplification was performed as follows: 94 °C, 1 min; 55 °C, 2 min; 72 °C, 2 min, 30 cycles. Successful results were obtained, comparable to those using fresh reagents. We observed molecules of equivalent size and amounts.
Example 9: Xylene and Toluene Extraction
PCR Buffer, nucleotides and Taq DNA Polymerase were co-solidified in Ampliwax, as above. lOOul of xylene or toluene was added on top of the co-solidified reagents. The tube was incubated for 30 minutes at 37 °C with vigorous vortexing about every five minutes. The dissolved wax and solvent were removed by pipetting. Water, primers and DNA template were added to the remaining agents. An Ampliwax pellet was added on top to prevent evaporation. The standard cycle program was used. A PCR product of the expected size was generated.
Industrial Applicability
The creation of compositions suitable to store and then deliver protein reagents into chemical reactions.
Claims
1. A reagent preparation comprising:
(a) an amount of a first wax carrier, the first wax carrier having a first melting point, and
(b) an amount of a first reagent wherein said first reagent is a substantially purified preparation of a protein reagent, said first wax carrier and said first reagent being combined to form a solid mixture when stored at a temperature less than the first melting point.
2. The preparation of claim 1 wherein the first melting point is greater than approximately room temperature.
3. The preparation of claim 1 wherein the first melting point is greater than approximately 37° C.
4. The preparation of claim 1 wherein the first melting point is greater than approximately 60 "C.
5. The preparation of claim 1 wherein the reagent is an enzyme.
6. The preparation of claim 5 wherein the reagent is a thermostable enzyme.
7. The reagent of claim 5 wherein the reagent is a enzyme selected from the group consisting of DNA polymerases, ligaεes, and restriction enzymes.
8. The preparation of claim 1 wherein the first reagent additionally contains a buffer or nucleotides.
9. The preparation of claim 1 wherein the first reagent is an antibody.
10. The preparation of claim 1 wherein the first reagent is a mixture of proteins .
11. The preparation of claim 1 wherein the first reagent is a protein-conjugated nucleotide.
12. The preparation of claim 1 wherein the carrier wax contains paraffin.
13. The preparation of claim 1 additionally comprising a second wax carrier, the second wax carrier having a second melting point, and a second reagent, wherein the second wax carrier and the second reagent are combined to form a solid mixture.
14. A method of delivering a protein reagent in a chemical reaction comprising the steps of:
(a) adding a portion of a preparation of a substantially purified first reagent to a portion of a liquified carrier wax, wherein a mixture is formed;
(b) cooling the mixture for a sufficient amount of time and at a sufficiently low temperature so that the mixture solidifies into a solid mixture;
(c) exposing the solid mixture to a second reagent, and wherein a reaction combination is formed; and
(d) releasing the first reagent, wherein the first and second reagent are free to react with one another.
15. The method of claim 14 wherein the releasing of the first reagent is by raising the temperature of the reaction mixture to a temperature greater than or equal to the melting point of the carrier wax.
16. The method of claim 14 wherein the releasing is by the addition of a solvent capable of dissolving the carrier wax.
17. The method of claim 14 wherein the solvent is an alcohol.
18. The method of claim 14 wherein the solvent is selected from the group consisting of xylene and toluene.
19. A method of preparing a stabilized reagent comprising the steps of
(a) combining a substantially purified preparation of a protein reagent with a carrier wax, wherein both the reagent preparation and the carrier wax are in liquid form; and
(b) cooling the combined reagent and carrier wax mixture at a sufficiently low temperature and for a sufficient time so that the combined mixture solidifies.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60296/94A AU6029694A (en) | 1993-01-19 | 1994-01-18 | Storage and delivery of purified protein reagents with carrier wax |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US488393A | 1993-01-19 | 1993-01-19 | |
US08/004,883 | 1993-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994017106A1 true WO1994017106A1 (en) | 1994-08-04 |
Family
ID=21713000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/000560 WO1994017106A1 (en) | 1993-01-19 | 1994-01-18 | Storage and delivery of purified protein reagents with carrier wax |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6029694A (en) |
WO (1) | WO1994017106A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795031A1 (en) * | 1994-12-02 | 1997-09-17 | Pharmacia Biotech Inc. | Sequential delivery of purified biological and chemical reagents |
EP1005652A1 (en) * | 1997-08-12 | 2000-06-07 | McIntyre, John A. | Antigens embedded in thermoplastic |
WO2001007581A1 (en) * | 1999-04-23 | 2001-02-01 | Nexttec Gmbh | Method for encapsulating macromolecules and/or particles and use thereof |
WO2007082693A2 (en) * | 2006-01-17 | 2007-07-26 | Ab Enzymes Gmbh | Improved enzyme formulations for animal feed |
US7611871B2 (en) | 2000-09-05 | 2009-11-03 | Biochip Technologies Gmbh | Method for the specific determination of DNA sequences by means of parallel amplification |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9388220B2 (en) | 2007-08-27 | 2016-07-12 | Longhorn Vaccines And Diagnostics, Llc | Immunogenic compositions and methods |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US9738923B2 (en) | 2014-06-18 | 2017-08-22 | Luminex Corporation | Methods for generating stabilized lyophilized materials |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
WO2021229549A1 (en) * | 2020-05-15 | 2021-11-18 | Universidade De Aveiro | Method and device for stabilizing and storing dna at room temperature and uses thereof |
WO2023119164A1 (en) * | 2021-12-21 | 2023-06-29 | Illumina Cambridge Limited | Wax-microsphere matrix compositions and methods of making and using the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991012342A1 (en) * | 1990-02-16 | 1991-08-22 | F. Hoffmann-La Roche Ag | Improvements in the specificity and convenience of the polymerase chain reaction |
EP0448930A1 (en) * | 1990-03-30 | 1991-10-02 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
-
1994
- 1994-01-18 AU AU60296/94A patent/AU6029694A/en not_active Abandoned
- 1994-01-18 WO PCT/US1994/000560 patent/WO1994017106A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991012342A1 (en) * | 1990-02-16 | 1991-08-22 | F. Hoffmann-La Roche Ag | Improvements in the specificity and convenience of the polymerase chain reaction |
EP0448930A1 (en) * | 1990-03-30 | 1991-10-02 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795031A4 (en) * | 1994-12-02 | 1999-06-02 | Pharmacia Biotech Inc | Sequential delivery of purified biological and chemical reagents |
EP0795031A1 (en) * | 1994-12-02 | 1997-09-17 | Pharmacia Biotech Inc. | Sequential delivery of purified biological and chemical reagents |
EP1005652A1 (en) * | 1997-08-12 | 2000-06-07 | McIntyre, John A. | Antigens embedded in thermoplastic |
EP1005652A4 (en) * | 1997-08-12 | 2002-06-26 | John A Mcintyre | Antigens embedded in thermoplastic |
EP1715342A1 (en) * | 1997-08-12 | 2006-10-25 | Embedded Concepts, LLC | Binding assay using antigens embedded in thermoplastic |
WO2001007581A1 (en) * | 1999-04-23 | 2001-02-01 | Nexttec Gmbh | Method for encapsulating macromolecules and/or particles and use thereof |
US7611871B2 (en) | 2000-09-05 | 2009-11-03 | Biochip Technologies Gmbh | Method for the specific determination of DNA sequences by means of parallel amplification |
WO2007082693A2 (en) * | 2006-01-17 | 2007-07-26 | Ab Enzymes Gmbh | Improved enzyme formulations for animal feed |
WO2007082693A3 (en) * | 2006-01-17 | 2007-09-07 | Syngenta Ltd | Improved enzyme formulations for animal feed |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9080204B2 (en) | 2006-09-12 | 2015-07-14 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009 |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9388220B2 (en) | 2007-08-27 | 2016-07-12 | Longhorn Vaccines And Diagnostics, Llc | Immunogenic compositions and methods |
US9777045B2 (en) | 2007-08-27 | 2017-10-03 | Longhorn Vaccines And Diagnostics, Llc | Immunogenic compositions and methods |
US10596250B2 (en) | 2007-08-27 | 2020-03-24 | Longhorn Vaccines And Diagnostics, Llc | Methods of treating and preventing influenza infections |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US9212399B2 (en) | 2007-10-01 | 2015-12-15 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and method of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US9416416B2 (en) | 2007-10-01 | 2016-08-16 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection/transport compositions and methods |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US10144954B2 (en) | 2014-06-18 | 2018-12-04 | Luminex Corporation | Methods for generating stabilized lyophilized materials |
US9738923B2 (en) | 2014-06-18 | 2017-08-22 | Luminex Corporation | Methods for generating stabilized lyophilized materials |
US11098344B2 (en) | 2014-06-18 | 2021-08-24 | Luminex Corporation | Methods for generating stabilized lyophilized materials |
US10087439B1 (en) | 2015-05-14 | 2018-10-02 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
WO2021229549A1 (en) * | 2020-05-15 | 2021-11-18 | Universidade De Aveiro | Method and device for stabilizing and storing dna at room temperature and uses thereof |
WO2023119164A1 (en) * | 2021-12-21 | 2023-06-29 | Illumina Cambridge Limited | Wax-microsphere matrix compositions and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
AU6029694A (en) | 1994-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU691385B2 (en) | Sequential delivery of purified biological and chemical reagents | |
WO1994017106A1 (en) | Storage and delivery of purified protein reagents with carrier wax | |
US6489116B2 (en) | Sensitive, multiplexed diagnostic assays for protein analysis | |
JP3087907B2 (en) | Improvement of specificity and simplicity of polymerase chain reaction | |
US5565339A (en) | Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents | |
JP2647794B2 (en) | Composition containing temperature-sensitive polymerase inhibitor, nucleic acid amplification method and monoclonal antibody | |
AU2005258951B2 (en) | Method for stabilising reagents which are useful for nucleic acid amplification | |
EP0820521B1 (en) | Biological reagent spheres | |
US20150141297A1 (en) | Methods and Compositions for Phototransfer | |
WO2006036845A1 (en) | Universal and target specific reagent beads for nucleic acid amplification | |
JPH0634759B2 (en) | Assay using template-dependent nucleic acid probe rearrangement | |
NO176362B (en) | Method and Reagent Combination for Determination of Nucleotide Sequences, and Application for Determination of Nucleotide Variation | |
MX2011011616A (en) | A dried and stabilized ready-to-use composition containing nucleic acid polymerization enzymes for molecular biology applications. | |
WO1996000301A1 (en) | Encapsulated pcr reagents | |
US11352619B2 (en) | Method for synthesis of polynucleotides using a diverse library of oligonucleotides | |
JP4651196B2 (en) | Method for making complementary oligonucleotide tag sets | |
US20210198718A1 (en) | Method of attaching adaptors to single-stranded regions of double-stranded polynucleotides | |
US20100081176A1 (en) | Enzyme-containing capsules and nucleic acid amplification kits | |
JP2002520073A (en) | Vector storage | |
US20230193147A1 (en) | Wax-microsphere matrix compositions and methods of making and using the same | |
EP3342851B1 (en) | Nucleic acid detection device and nucleic acid detection method | |
JPH03236781A (en) | Random primer kit and usage thereof | |
JPH03147787A (en) | New method for cloning dna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |